Aimee Merino, MD

Panelists discuss the future treatment landscape for early relapsed/refractory multiple myeloma, emphasizing the evolving role of community providers, the implications for patient access to care, and how emerging data will influence treatment sequencing in subsequent lines of therapy.

Panelists discuss treatment options for patients ineligible for chimeric antigen receptor T-cell therapy in the second-line setting, focusing on the selection of new proteasome inhibitors and/or immune-mediated immunomodulatory drugs vs recycling combination regimens, and reviewing recent data from the APOLLO and IKEMA trials that support the use of combination therapies in relapsed/refractory multiple myeloma.

Panelists discuss the correlation between early and late toxicities observed in clinical practice for patients receiving chimeric antigen receptor T-cell (CAR T) therapy in early relapsed/refractory multiple myeloma and their perceptions of the latest International Myeloma Working Group Consensus Guidelines on response assessment and management of CAR T–related adverse events.

Aimee Merino, MD, discusses how the latest efficacy outcomes from the CARTITUDE-4 trial, evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma, have influenced her approach to patient selection and referral for chimeric antigen receptor T-cell therapy in early relapse cases.

Aimee Merino, MD, discusses how the referral process for chimeric antigen receptor T-cell therapy in early relapsed/refractory multiple myeloma involves assessing eligibility, identifying potential roadblocks, and determining which patients may not be suitable for referral based on clinical factors and treatment goals.

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, distinguishing functional high-risk patients from those with standard risk, and tailoring treatment strategies accordingly.

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple myeloma, involving chimeric antigen receptor (CAR) T-cell therapy, aligns with the goals of therapy while exploring alternative treatment options and considerations for high-risk patients.